| NovoLog Onset | 10β20 minutes |
| Humalog Onset | 15β30 minutes |
| NovoLog Peak | 1β3 hours |
| Humalog Peak | 1β2 hours |
| NovoLog Duration | 3β5 hours |
| Humalog Duration | 3β4 hours |
| Drug Class | Rapid-acting insulin analog |
| Administration | Subcutaneous injection or insulin pump |
Key Takeaways
- Both NovoLog (insulin aspart) and Humalog (insulin lispro) are rapid-acting analogs used at mealtimes.
- NovoLog acts slightly faster; Humalog has a marginally shorter duration in some studies.
- Choice often depends on insurance coverage, pump compatibility, and individual response.
- Always consult your endocrinologist before switching insulins.
Overview
NovoLog (insulin aspart, by Novo Nordisk) and Humalog (insulin lispro, by Eli Lilly) are the two most prescribed rapid-acting insulin analogs in the United States. Both are engineered to mimic the body's natural mealtime insulin surge, controlling post-meal blood glucose spikes more effectively than older regular insulin.
How They Work
Both insulins are modified human insulin analogs. NovoLog replaces proline with aspartic acid at position B28, reducing self-aggregation so it absorbs faster. Humalog swaps proline and lysine at positions B28 and B29, achieving a similar rapid-absorption effect.
Pharmacokinetic Comparison
| Property | NovoLog (Aspart) | Humalog (Lispro) |
|---|---|---|
| Onset | 10β20 minutes | 15β30 minutes |
| Peak | 1β3 hours | 1β2 hours |
| Duration | 3β5 hours | 3β4 hours |
| Injection timing | 0β10 min before meal | 0β15 min before meal |
Pump Compatibility
Both insulins are approved for use in continuous subcutaneous insulin infusion (CSII) pumps. However, NovoLog has broader labeling data for pump use and is often the default choice for insulin pump users. Humalog is equally effective but check your specific pump manufacturer's recommendations.
Biosimilars & Cost
Cost is a major deciding factor. Admelog (insulin lispro biosimilar) competes with Humalog at lower prices. Fiasp, Novo Nordisk's next-generation aspart, acts even faster than NovoLog. Generic and biosimilar options can reduce out-of-pocket costs significantly β always check your formulary.
Side Effects & Hypoglycemia Risk
Both carry similar hypoglycemia risks. Because they act faster than regular insulin, timing meals correctly is critical. Missing a meal after injection can cause dangerous low blood sugar. Injection site reactions are rare but possible with both.
Which Should You Choose?
Clinical outcomes between NovoLog and Humalog are largely equivalent in head-to-head trials. The practical decision usually comes down to: insurance formulary coverage, pump compatibility, pen device preference, and individual glycemic response. Some patients find one controls post-meal spikes better β this is highly individual.
Monitoring Your Response
Whichever insulin you use, consistent blood glucose monitoring is essential. Pairing rapid-acting insulin with a reliable glucose meter helps you fine-tune dosing timing and amount. MDS Diabetes offers a range of glucose meters, insulin pen needles, and diabetes management supplies compatible with both NovoLog and Humalog regimens.